Evidence map›Paper›PMID 41027867›Full record

Trial reportNature communications2025

Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy.

Dominic Schmid, Bettina Sobottka, Massimiliano Manzo, Marta Trüb, Katharina Leonards, Petra Herzig, Oluwaseun Rume-Abiola Oyewole, Philip Jermann, Stefanie Hayoz, Spasenija Savic Prince and 21 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non-Small Cell Lung Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Dominic Schmid *Laboratory of Cancer Immunology, Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland. dominic.schmid@unibas.ch.ORCID http://orcid.org/0000-0003-4821-6495
Bettina Sobottka *Department of Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Massimiliano Manzo *Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Marta TrübLaboratory of Cancer Immunology, Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland.
Katharina LeonardsInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0002-4004-3473
Petra HerzigLaboratory of Cancer Immunology, Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland.
Oluwaseun Rume-Abiola OyewoleInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Philip JermannInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Stefanie HayozSwiss Cancer Institute, Bern, Switzerland.ORCID http://orcid.org/0000-0002-2265-6559
Spasenija Savic PrinceInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Giulia TochtermannDepartment of Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Marina NatoliLaboratory of Cancer Immunology, Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland.
Miklos PlessSwiss Cancer Institute, Bern, Switzerland.
Adrienne BettiniDepartment of Oncology, HFR Fribourg, Fribourg, Switzerland.
Martin FrühDepartment of Oncology/Hematology HOCH, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Laetitia A MautiDepartment of Oncology, Cantonal Hospital Winterthur, Winterthur, Switzerland.ORCID http://orcid.org/0000-0002-6652-1947
Christian BritschgiDepartment of Oncology, Cantonal Hospital Winterthur, Winterthur, Switzerland.ORCID http://orcid.org/0000-0001-8831-1564
Solange PetersDepartment of Oncology, University Hospital Lausanne CHUV, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-0412-7143
Michael MarkDivision of Oncology/Hematology, Cantonal Hospital Graubünden, Chur, Switzerland.
Adrian F OchsenbeinDepartment of Oncology, Inselspital University Hospital Berne, Berne, Switzerland.ORCID http://orcid.org/0000-0003-1773-5436
Wolf-Dieter JanthurDepartment of Oncology/Hematology, Cantonal Hospital Aarau, Aarau, Switzerland.
Christine WaibelDepartment of Internal Medicine, Center for Oncology and Hematology, Cantonal Hospital Baden, Baden, Switzerland.
Nicolas MachDepartment of Oncology, University Hospital Geneva, Geneva, Switzerland.ORCID http://orcid.org/0000-0001-8944-1088
Patrizia FroeschOncology Institute of Southern Switzerland, Bellinzona, Switzerland.
Martin BuessDivision of Medical Oncology, St Claraspital, Basel, Switzerland.ORCID http://orcid.org/0000-0001-6590-1203
Pierre BohanesCentre de Chimiothérapie Anti-Cancéreuse, Lausanne, Switzerland.
Michel GonzalezDepartment of Thoracic Surgery, University Hospital Lausanne CHUV, Lausanne, Switzerland.ORCID http://orcid.org/0000-0001-8705-4279
Ilaria AlborelliInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0001-7849-3958
Sacha I RothschildLaboratory of Cancer Immunology, Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0003-1304-9340
Viktor Hendrik KoelzerDepartment of Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Alfred ZippeliusLaboratory of Cancer Immunology, Department of Biomedicine, University of Basel and University Hospital of Basel, Basel, Switzerland. alfred.zippelius@usb.ch.ORCID http://orcid.org/0000-0003-1933-8178

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neoadjuvant chemoimmunotherapy offers promise to improve outcomes for patients with resectable non-small cell lung cancer (NSCLC). Yet not all patients derive treatment benefits, and reliable biomarkers of response are still lacking. We here assess the long-term clinical outcome of neoadjuvant chemotherapy and perioperative anti-PD-L1 inhibition in resectable stage IIIA NSCLC in the SAKK 16/14 trial and provide a comprehensive characterization of anti-tumor immune responses for biomarker-based treatment personalization. We report secondary outcomes of median event-free survival (EFS) of 4.0 years and median overall survival not being reached after a median follow-up of 5.4 years. Computer-aided spatial image analysis emphasizes the importance of CD8

Indexed as

Carcinoma, Non-Small-Cell LungImmunotherapyLung NeoplasmsNeoadjuvant TherapyAgedB7-H1 AntigenCD8-Positive T-LymphocytesFemaleHumansImmune Checkpoint InhibitorsMaleMiddle AgedNeoplasm StagingTreatment OutcomeB7-H1 AntigenCD274 protein, humanImmune Checkpoint Inhibitors

Identifiers

PMID41027867
PMCPMC12484868

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.